Danuta Sielska-Rotblum

Dr. Danuta Sielska-Rotblum

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MKMarzena Kucharczyk
Marzena Kucharczyk
AKAdam Kochanski
Adam Kochanski
AJAleksandra Jezela‐Stanek
Aleksandra Jezela‐Stanek
MKMonika Kugaudo
Monika Kugaudo
DSDanuta Sielska-Rotblum
Danuta Sielska-Rotblum
MKMałgorzata Krajewska-Walasek
Małgorzata Krajewska-Walasek

2 September 2016 in Genes
Verified
Journal Article
Open access
PDF file
SRSylwia Rzońca
Sylwia Rzońca
GMGos Monika
Gos Monika
DSDaniel Szopa
Daniel Szopa
DSDanuta Sielska-Rotblum
Danuta Sielska-Rotblum
ALAleksandra Landowska
Aleksandra Landowska
JBJerzy Bal
Jerzy Bal
The article summarizes over 20 years of experience of a reference lab in fragile X mental retardation 1 gene (FMR1) molecular analysis in the molecular diagnosis of fragile X spectrum disorders. This includes fragile X syndrome (FXS), fragile X-associated primary ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS), which are three different clinical conditions with the same molecular background. They are all associated with an expansion of CGG repeats in the 5′UTR of FMR1 gene. Until 2016, the FMR1 gene was tested in 9185 individuals with the pre-screening PCR, supplemented with Southern blot analysis and/or Triplet Repeat Primed PCR based method. This approach allowed us to confirm the diagnosis of FXS, FXPOI FXTAS in 636/9131 (6.96%), 4/43 (9.3%) and 3/11 (27.3%) of the studied cases, respectively. Moreover, the FXS carrier status was established in 389 individuals. The technical aspect of the molecular analysis is very important in diagnosis of FXS-related disorders. The new methods were subsequently implemented in our laboratory. This allowed the significance of the Southern blot technique to be decreased until its complete withdrawal. Our experience points out the necessity of implementation of the GeneScan based methods to simplify the testing procedure as well as to obtain more information for the patient, especially if TP-PCR based methods are used.

25 February 2026 in Genes
Verified
Journal Article
Open access
PDF file
MMMarlena Mlynek
Marlena Mlynek
DWDorota Wicher
Dorota Wicher
ACAgata Maria Cieślikowska
Agata Maria Cieślikowska
KUKatarzyna Urbańska
Katarzyna Urbańska
KPKamila Przywoźna-Zduńczyk
Kamila Przywoźna-Zduńczyk
AMAgnieszka Madej-Pilarczyk
Agnieszka Madej-Pilarczyk
Objective: Copy number variants (CNVs) overlapping genes associated with neurodevelopmental disorders in patients with epilepsy are particularly concentrated in epilepsy hotspot loci. The aim of this study was to evaluate epilepsy as a component of the dysmorphic–neurodevelopmental phenotype in patients with recurrent CNVs. Methods: The study included genetic and clinical data from 177 pediatric patients carrying 17 recurrent CNVs showing well-documented enrichment in epilepsy or associated with genetic OMIM syndromes. Results: Epilepsy was diagnosed in 50 of 177 children (28.2%), developmental delay in 147 (83.0%), dysmorphic features in 104 (58.8%), behavioral problems in 62 (35.0%), and congenital anomalies in 55 (31.1%). Among recurrent CNV hotspots, the del16p11.2 BP4–BP5 deletion was the most frequent, occurring in 39 of 177 patients. Ten children (25.6%) with del16p11.2 presented with epilepsy as part of the phenotype. Other frequently represented CNVs included del15q11.2 BP1–BP2 (OMIM #615656; 19/177 patients, 4/19 with epilepsy), del1q21.1 (OMIM #612474; 15/177, 6/15 with epilepsy), del15q13.3 (OMIM #612001; 13/177, 4/13 with epilepsy), and dup16p11.2 (OMIM #614671; 12/177, 1/12 with epilepsy). The highest proportion of epilepsy as a phenotypic component was observed in patients with del1p36 (OMIM #607872; 6/9 patients) and del1q21.1 (OMIM #612474; 6/15 patients). Conclusions: Our data support the clinical utility of CNV testing in patients with epilepsy accompanied by additional neurodevelopmental or dysmorphic features, in line with current diagnostic guidelines. The epilepsy-plus phenotype may help clinicians identify patients who are most likely to benefit from CNV analysis.